INTRODUCTION
============

Finding bacilli in a cutaneous tuberculosis (CTB) lesion is a challenge. On average, all diagnostic methods have lower sensitivity and specificity rates for cutaneous presentations compared to the pulmonary form. Considering that atypical erythema nodosum and nonspecific appearance are not uncommon, and also that histopathology may not be elucidative, physicians must resort to every possible test, so that the sum of positive elements can create the basis for diagnosis, thus reducing empirical treatments or those based solely on the positivity of tuberculin test.

Therefore, when confronted with the hypothesis of CTB, beyond mandatory tuberculin skin test (TST) and chest radiograph for all patients, it is of paramount importance to collect material for histopathological examination and also separate samples for acid-fast bacilli (AFB) detection through culture and amplification of *Mycobacterium tuberculosis* (Mtb) DNA by polymerase chain reaction (PCR) both in the sample as well as in the blood.

Several laboratory methods have been developed to increase the accuracy of diagnosis in cases of latent tuberculosis or when there is doubt, based on the dose intensity of interferon production and improvement of the culture medium. In cases of pulmonary tuberculosis the Ministry of Health recommends offering HIV testing to all patients. Although for cutaneous tuberculosis no such recommendation exists, it is common sense that the aforesaid measure should also be adopted. The introduction of this routine will definitely increase the number of diagnoses.

LABORATORY DIAGNOSIS
====================

**A - Tuberculin skin test (TST)** - The tuberculin test identifies individuals sensitized to *Mtb*. The test becomes positive in 2 to 10 weeks after the infection. This technique involves intradermal injection of tuberculin purified protein derivative materials (PPD) on the front surface of the left forearm, followed by reading after 48 to 72 hours when the size of induration is measured (Mantoux technique). In Brazil the PPD-RT23 protein is used. False negative reactions can occur in children under two months old, pregnant women, patients with diabetes, renal failure, or impaired cellular immunity. On the other hand recent vaccination, particularly in children over one year and co-infection with atypical mycobacteria are causes of false positive tests.^[@r01]^ The patient is considered as a strong reactor when the induration is greater than or equal to 5mm for patients with AIDS and above 10 mm for those without immune deficiency, for all disease presentations. So it is vital to evaluate the seropositivity for HIV1 and 2 in all patients.

For cutaneous tuberculosis, TST has sensitivity between 33% and 96% and specificity of 62.50% with a cutoff of 10 mm. In unvaccinated populations, the sensitivity is much higher, close to 97%.^[@r02],[@r03]^

Analyzing each clinical presentation separately, positivity and intensity of the tuberculin skin test also vary. Tuberculous chancre, miliary tuberculosis and tuberculosis orificialis (the latter mainly by association with AIDS), commonly show negative results. Scrofuloderma and lupus vulgaris are the forms that, more often, present strongly reactive tests. Therefore, the other forms are those with more variable results for TST.^[@r04],[@r05]^

The increase in the TST cutoff value did not resulted in increased diagnosis accuracy (chance to detect cases), because while there is an increment in sensitivity, there is also a decline in specificity. In other words, the higher the TST value, the greater chance the subject has tuberculosis, but the lower the utility in screening the population because many positive individuals will not be accounted for.

This value of 10 mm may not, however, be optimal for assessing cases of cutaneous tuberculosis, especially the paucibacillary ones. The higher accuracy of TST would be between 7 and 9 mm. It would be interesting that other studies were conducted to enlighten this point, thus making it possible to determine the best TST values specifically for CTB and maybe to identify values for different paucibacillary and multibacillary forms.^[@r02]^

**B - Interferon-gamma release assays**

These are serological tests that assess latent infection by measuring interferon-gamma produced by T-cells in individuals who were exposed to *Mtb* antigens, resulting in fewer errors especially in endemic areas and in populations vaccinated with BCG. However, previous infections by environmental mycobacteria such as *M. marinum* and *M. kansasii* may produce false positive results.

Currently there are two tests commercially available and approved by the FDA, QuantiFERON-TB Gold (QFT-G) and T-SPOT.TB. A systematic review of 38 studies that evaluated the sensitivity and specificity of the two tests for tuberculosis in general found an average sensitivity for QFT-G of 76% (Confidence Interval of 95% (CI95%: 72%-80%) and for T-SPOT.TB of 90% (CI95%: 86%-93%). Regarding specificity, there was an inversion, with QFT-G showing the highest rate 99% (CI 95%: 98%-100%) amongst unvaccinated patients and 96% (CI95%: 94%-98%) amongst the vaccinated ones, than T-SPOT.TB 93% (CI95%: 86%-100%) in both groups.^[@r06]^

These values are valid for pulmonary TB cases. A prospective study using T-SPOT.TB in 45 patients suspected of cutaneous tuberculosis found a sensitivity of 91.6% (CI95%: 64.6%-98.5%), a value similar to that found in cases of pulmonary tuberculosis, but with lower reproducibility (larger CI) and even lower specificity 75.8% (CI95%: 59%-87.2%), precisely because of the false positive results due to atypical cutaneous mycobacteria.^[@r07]^

Despite the higher sensitivity and specificity of the method compared to TST, it may have indeterminate results in elderly patients (over 65 years old), in about 30% of cases, while in other age groups this index is 3.1%. There is a higher proportion of false negatives in this age group compared to others, 58.3% versus 25%. Other groups with high rates of indeterminate results are those patients with a history of previous severe disease requiring ICU admission, malnourished or lymphopenic individuals especially when there is low CD4 counts, those with increased Creactive protein serum levels or decreased total protein levels. Below 35 years of age, when none of these situations is present, the error rate approaches zero.^[@r03],[@r08]^

It is extremely important to emphasize that most studies were conducted in countries where tuberculosis is not endemic. That is, the effect of vaccination was considered, but not the environmental exposure to *Mtb*. Another crucial consideration is the possibility that an influence of the population studied in the results might occur, because of the difference in the genetic pool. Ideally, there should be national studies to confirm these values in our population that has a characteristic of racial miscegenation.

The advantage of this type of testing is not limited to issues of vaccination, other utilities are the screening for latent tuberculosis in patients who are undergoing anti-TNF alpha therapy, for those with kidney disease or submitted to transplant, to aid the diagnosis of difficult situations such as in children and contacts of patients with AIDS, and to clarify the etiology of erythema induratum and erythema nodosum secondary to TB.^[@r09]-[@r12]^

**C - Investigation of acid-fast bacilli in stained smear:** this technique presents faster results than culture. Ziehl-Neelsen acid staining is the most used stain for this purpose. The diagnostic yield of smears is higher for wet or exudative lesions, because they have a higher bacterial load, as is the case with CTB by primary inoculation, scrofuloderma, tuberculosis orificialis, or metastatic tuberculous abscess.^[@r01]^

**D - Mycobacterial culture:** it is the gold standard for determining the presence of active TB infection, and it can also distinguish mycobacteria subspecies and determine antibiotic susceptibility. Culture sensitivity is much lower than its specificity, with 80-85% and 98.5% respectively in the pulmonary forms of TB. In an exclusively cutaneous presentation, positivity is even lower, around 23% in traditional media. The introduction of radiometric culture media, increased the positivity to 75% for CTB, however, these media are not accessible or known to everyone. The dermatologist must remember to request specifically for mycobacteria culture.^[@r13]^

**E - Polymerase chain reaction (PCR):** It is mainly used as a complement to clinicopathological assessment. In this test, *Mtb* DNA present in a sample of fresh tissues, blood or a paraffin block is amplified and it can then be identified, confirming the presence of mycobacteria.^[@r14],[@r15]^

There are different manners to amplify DNA as described below:

1.  Conventional or in-house PCR: a manual system, standardized by each laboratory, in which it a sequence of DNA previously selected is amplified through the use of oligonucleotides (primers) that mark the beginning of that sequence and DNA polymerase that helps replicate that segment.^[@r15],[@r16]^

2.  Real-time PCR: it is an automated process, wherein the selected fragment is always the same and is associated with a system that captures the fluorescent light originating from the amplification. Therefore, immediately after amplification, the light emission is used to confirm the results. The advantages over traditional amplification are decrease in equipment contamination, loss of material and operatordependent errors. Nevertheless, in other situations there seems to be no difference in sensitivity and specificity between this technique and the conventional method.^[@r15],[@r16],[@r17]^

3.  PCR with hybridization: after amplification DNA is selected by a marker. Then the sample is placed in an ELISA plate, where there is a probe that binds to an inner portion of the fragment. The reaction between the marker and the probe produces a color that can be identified and quantified by spectrophotometer. It increases the chances of detecting DNA and reduces false negatives.^[@r15],[@r16]^

4.  *In situ* PCR: it is a process in which hybridization occurs in the tissue, including in paraffin slides, thus demonstrating the location of mycobacterial DNA within the cell. It has a lower sensitivity than traditional PCR. Hybridization can be done in situ, subsequently, to increase the chance of positivity.^[@r15],[@r16]^

**F - Genotyping:** this is the study of different techniques for molecular typing of *Mtb* strains; it helps in the sequencing of resistance genes to assess mutations and correlate the results of molecular epidemiology with data from classical epidemiology. These data have revolutionized the understanding of tuberculosis\' epidemiology. With the amplified DNA, it is also possible to separate atypical mycobacteria from *Mtb,* genotype mycobacteria and detect mutations that induce resistance to antibiotics.^[@r17],[@r18]^ The main molecular typing methods are:

1.  ***Spoligotyping*** (Spacer Oligonucleotide Typing): Specific test to assess the presence of polymorphism of locus DR (Direct Repeat), found exclusively in the genome of *Mtb* complex mycobacteria. It uses a smaller amount of DNA, which increases the sensitivity of the method. It is considered the gold standard for genotyping and indicates the strain of mycobacteria.^[@r15],[@r17]^

2.  **RFLP** (Restriction Fragment Length Polymorphism): Uses the insertion sequence IS6110 in the genome of *Mtb* strains. It is used to study outbreaks, epidemics or to study population genetics. In this method, *Mtb* DNA is cleaved with restriction enzymes.

3.  **MIRU-VNTR** (mycobacterial interspersed repetitive units-variable number of tandem repeats): standardized technique in which 12, 15 or 24 polymorphic loci of the MIRU-VNTR family are amplified. Then, electrophoresis is performed allowing the visualization and identification of these loci, thus classifying the family of the mycobacteria.

Most authors use *in situ* PCR as a complementary test to histological examination, especially for undefined cases. However, the results must be understood within the context of the clinical presentation. Tan et al. studied the larger number of cases (105), which permitted even their separation by type of clinical lesions. PCR was 100% sensitive and specific in immunocompromised patients with multibacillary forms. In paucibacillary forms, there was positivity of 55% in cases of tuberculosis verrucosa and 60% in cases of lupus vulgaris. For cases of *erythema induratum* positivity was 54%. Considering all cases, the mean sensitivity was 73%.^[@r19]^ In contrast with these results, Senturk et al. observed only one case with positive result amongst 22 confirmed cases of CTB. The study was a retrospective analysis of archived blocks, possibly demonstrating a loss of sensitivity with time.^[@r20]^ A similar result was obtained by Hsiao et al. while evaluating only paucibacillary cases, the authors found 18 positive results in 34 cases, resulting in a sensitivity rate of 56.2%.^[@r21]^

More recently, Abdalla et al. in a prospective study that compared PCR with other diagnostic methods, attributed a higher sensitivity and specificity rates to it than to other methods (sensitivity 88% and specificity 83%), however, the author concluded that clinical presentation is still the main key in the process of CTB diagnosis.^[@r22]^

HISTOPATHOLOGY
==============

All CTB clinical presentations have a similar histological basis, composed of lymphocytes, epithelioid histiocytes and giant cells; the histological differences observed for each clinical presentation result from the variation in the host\'s ability to organize the granulomatous process ([Figures 1](#f01){ref-type="fig"} and [2](#f02){ref-type="fig"}). In a didactical manner, we can divided CTB\'s histology in three groups in order to emphasize the concept that the intensity of the host\'s immune response is responsible for the clinical and pathological presentation of the disease: well-formed granulomas with absence of caseous necrosis, granulomas with caseous necrosis and the presence of poorly formed granulomas with intense caseous necrosis.^[@r01],[@r23]-[@r25]^
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A - Well-formed granulomas with absence of caseous necrosis
-----------------------------------------------------------

**Lupus vulgaris:** the epidermis may be atrophic or hypertrophic, featuring acanthosis, papillomatosis and even pseudoepitheliomatous hyperplasia. Presence of well-formed tuberculous granulomas accompanied more often by Langhans giant cells, or foreign body-like granulomas in the reticular dermis. There may be sarcoidosis-like granulomas ([Figure 2](#f02){ref-type="fig"}). The lymphocytic infiltrate is dense and caseous necrosis is rarely present, but it will occur in small foci centrally to the granuloma. The observation of AFB is infrequent ([Figure 3](#f03){ref-type="fig"}).

![Epidermic hyperplasia accompanied by granulom atous inflammatory process with necrosis foci, without caseous, in lupus vulgaris](abd-89-04-0545-g03){#f03}

**Lichen scrofulosorum:** presence of epithelioid granulomas surrounded by lymphocytes and located more superficially in the dermis adjacent to the adnexa. Normally giant cells are absent. Caseous necrosis and acid-fast bacilli are not found ([Figure 4](#f04){ref-type="fig"}).

![Discrete rectification of the epidermis accompanied by well-formed lymphoh istiocytic granulomas with a superficial location in lichen scrofulosorum](abd-89-04-0545-g04){#f04}

B - Intermediate forms: granulomas with caseous necrosis
--------------------------------------------------------

**Tuberculosis verrucosa cutis:** presence of prominent epidermal changes such as hyperkeratosis, acanthosis and papillomatosis. At the same time, tuberculous granulomas with caseous necrosis of moderate intensity are seen in the dermis and bacilli can be found.

**Primary cutaneous tuberculosis:** it varies according to the time of inoculation; in recent lesions there is the presence of necrotizing neutrophilic infiltrate with numerous AFB. At a later stage there is organization of granulomas and decreased numbers of bacilli.

**Acute miliary tuberculosis:** there is a nonspecific inflammatory infiltrate, rich in lymphocytes and plasma cells; caseous necrosis, if present, is of a focal nature, and occasionally micro-abscesses are observed. Presence of bacilli varies directly with the severity of the condition.

**Tuberculosis orificialis:** there are tuberculoid granulomas, around a median, central, superficial ulcer accompanied by caseous necrosis in the deep dermis.

**Papulonecrotic tuberculid:** presence of an area of necrosis into the dermis, accompanied with granulomatous infiltrate, leukocytoclastic vasculitis, perivascular edema or follicular necrosis with suppuration.

C - Poorly formed granulomas with intense caseous necrosis
----------------------------------------------------------

**Scrofuloderma:** Massive central necrosis with abscess formation and in many cases, suppuration ([Figure 3](#f03){ref-type="fig"}). At the periphery of the lesion traces of granulomas can be observed. When present *Mycobacterium tuberculosis* can also be found in this location ([Figure 5](#f05){ref-type="fig"}).

![Caseous necrosis surrounded by granulomatous process in scrofuloderma](abd-89-04-0545-g05){#f05}

**Metastatic abscesses and gumma:** Central ulceration with abundant caseous necrosis, surrounded by a rim of giant cells and macrophages. AFBs are frequently detected.

Histopathological examination is essential to complement the investigation of CTB cases, however, in most samples, the bacillus cannot be observed even when special staining techniques are performed. In case series studies, the presence of AFB in samples is very low, ranging from 0 to 5% of the total samples.^[@r26]-[@r30]^ A single work performed in Nepal found a different percentage of observation of bacilli, 35 observations on 50 specimens, an unusual fact.^[@r29]^

The most common histological finding in CTB is the tuberculoid granuloma in the dermis, observed in 57% to 96% of the samples.^[@r27],[@r29]^ Nevertheless, it should be remembered that other types of granuloma can also be found in CTB, such as annular-like granuloma formations, sarcoid granuloma and suppurative granuloma.^[@r30]^ Therefore when there is other evidence for CTB and also the presence of one of these histological elements, the diagnosis of cutaneous tuberculosis cannot be discarded.

The other two most important findings, in decreasing order of frequency, are the epidermal hyperplasia and caseous necrosis, with observation in histological examinations varying from 57% to 86% and from 11,8% to 57%.^[@r24],[@r26],[@r27]^ The first is more common in verrucous forms, and the second is observed in inflammatory forms.

Besides the absence of the bacillus, the difficulty in confirming a CTB diagnosis based on histology is also due to the fact that, characteristics considered suggestive or typical of the disease are not always found. Umaphaty et al. observed that 14% of samples from confirmed cases presented no aspect suggestive of CTB, making it impossible to predict the diagnosis solely from histology.^[@r26]^ This occurs because of the histological similarity between CTB, and other infectious granulomatous diseases, sarcoidosis, and granulomatous rosacea. Studies comparing the histological elements have attempted to bring some light to this issue by trying to find histological elements that can serve as a guide for difficult cases. However there are few articles on this topic, with a small number of patients and comparing tuberculosis with only one other infectious disease, which restricts the use of the data found ([Chart 1](#t01){ref-type="table"}).

###### 

Comparative histological studies on cutaneous tuberculosis

  **Author /year**                       **Type of study**                                                      **Conclusions**
  -------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Nimala et al India, 1977               20 cases of CTB versus                                                 In CTB \> frequency of epidermic hyperplasia, small areas of ulceration, significant fibrosis and occasional caseous necrosis
  20 cases of tuberculoid leprosy                                                                               
  Paksoy and Hekim Turkey, 1993          16 cases of lupusvulgaris versus 12 cases of cutaneous leishmaniasis   Tuberculoid granulomas and giant cells are more frequent in CTB
  Min et al South Korea, 2012            15 cases of CTB versus                                                 Giant cells, tuberculoid granulomas, and caseous necrosis were significantly associated to CTB (p\< 0.05).
  10 cases of atypical mycobacteriosis                                                                          

Due to the difficulty in finding the etiologic agent in question, the use of other complementary tests, clinical follow-up and often implementing therapeutic tests are needed to confirm many cases. A simple way to increase the sensitivity of histopathology is to add the tuberculin skin test (TST) and / or serum PCR in the fragment or in the biopsy slide. Hence, compared to clinical suspicion, a histopathological examination with suggestive aspects, plus a strong positive TST reaction is highly suggestive of CTB.

TREATMENT
=========

Tuberculosis is curable in virtually 100% of new cases, as long as the basic principles of drug therapy and the proper management of the treatment are observed. The appropriate combination therapy, the correct doses, and the use of medications for long enough, are the basic principles to prevent bacterial persistence and the development of drug resistance, thus ensuring the patient\'s cure.

The recommended treatment since 1979, known as RIP (rifampicin, isoniazid, pyrazinamide) was modified in 2009 due to the preliminary results of the Second National Survey on Anti-TB drugs Resistance, in which an increase in primary isoniazid resistance, from 4.4 to 6.0%, was found. This fact led to the addition of ethambutol (E) as a fourth drug in the intensive phase of treatment (first two months). Thus, the basic treatment regimen for tuberculosis now has, mandatorily, four drugs (RIPE).

The treatment of all extrapulmonary forms (except meningoencephalitis) lasts six months, as well as the treatment of patients co-infected with HIV, regardless of the stage of evolution of viral infection. Meningoencephalitic forms are treated for nine months. Medications should be administered preferably on an empty stomach (1 hour before or two hours after breakfast) in a single intake or in case of digestive intolerance, with a meal.

A - Basic Treatment Scheme for Adults and Teenagers
---------------------------------------------------

Recommended for all new cases in adults and adolescents (\>10 years), all forms of pulmonary and extrapulmonary tuberculosis (except meningoencephalitis), as well as all cases of relapse and return after treatment dropout ([Chart 2](#t02){ref-type="table"}).

###### 

Treatment for TB - adult and teenagers CTB

  **Regimen**                                **Drugs**     **Weight Range**                                                **Unit/dose**                   **Months**
  ------------------------------------------ ------------- --------------------------------------------------------------- ------------------------------- ------------
  Intensive phase                            **RHZE**      20 to 35 Kg                                                     2 tablets                       2 Months
  150/75/400/275mg                           36 to 50 Kg   3 tablets                                                                                       
  Tablet with combined fixed-dose            \>50 Kg       4 tablets                                                                                       
  Maintenance Phase                          **RH**        20 to 35 Kg                                                     1 capsule or tablet 300/200mg   4 Months
  300/200mg or 150/100mg capsule or tablet   36 to 50 Kg   1 capsule or tablet 300/200mg + 1 capsule or tablet 150/100mg                                   
                                             \>50 Kg       2 capsules or tablets 300/200mg                                                                 

**R:** rifampicin; H: isoniazid; Z: pyrazinamide; E: ethambutol

**\*** In the first months of implementation of the new scheme, the maintenance phase will continue with capsules.

B - Basic Treatment scheme for Children (2RHZ/4RH) ([Chart 3](#t03){ref-type="table"})
--------------------------------------------------------------------------------------

###### 

Treatment for TB - children (under 10 years-old)

  **Regimen**         **Drugs**   **Patient\'s weight**                                                          
  ------------------- ----------- ------------------------- ------------------------- ------------------------- -------------------
                                  Up to 20kg \> mg/Kg/day   \>20 to 35kg mg/Kg/ day   \>35 to 45kg mg/Kg/ day   \>45kg mg/Kg/ day
  2RHZ                R           10                        300                       450                       600
  Attack Phase        H           10                        200                       300                       400
                      Z           35                        1000                      1500                      2000
  4RH                 R           10                        300                       450                       600
  Maintenance Phase   H           10                        200                       300                       400

**R:** : rifampicin; H: isoniazid; Z: pyrazinamide

C - Treatment for special situations
------------------------------------

•Pregnancy
----------

Extrapulmonary tuberculosis does not seem to be more frequent in pregnant women. With respect to therapeutic regimens, the use of ethambutol and streptomycin are contraindicated due to their teratogenic effects. There are not, to date, evidence of teratogenic effects with the use of rifampin, isoniazid, pyrazinamide and ethambutol, allowing treatment normally during pregnancy. In pregnant women in treatment with isoniazid, pyridoxine (25mg/day) is used as a prophylactic agent against peripheral neuritis, and seizures in newborns. Breastfeeding should be encouraged due to the low concentration of these drugs in breast milk.

• Elder patients
----------------

Treatment is the same, adjusting the dose according to body weight, and knowing that changes in metabolism, morphology and homeostasis, besides concomitant use of numerous medications, favor the appearance of adverse events in the elderly.

• Renal Insufficiency
---------------------

The interval or drug dosing should be adjusted in patients with creatinine clearance \<30ml/min. If the creatinine clearance is\> 30ml/min, the standard dose should be used, with monitoring of drug serum levels whenever possible.

• Hepatic Insufficiency
-----------------------

The treatment of patients with liver disease requires special considerations since rifampicin, isoniazid and pyrazinamide have great hepatotoxicity potential, increasing the likelihood of liver damage. Monitoring of drug-induced hepatitis is also hampered by higher fluctuating levels of liver enzymes secondary to the underlying condition.^[@r30]^ Isoniazid has a longer half-life and consequently higher serum levels in patients with liver disease and also in those over 50 years old. Ethambutol is the only drug that can be fully utilized by patients with liver insufficiency.^[@r31]^

Patients with transaminase values up to 3 times the normal can be treated with scheme I, but laboratory exams should be monitored monthly. If transaminase values are above that, scheme I can be replaced, usually suspending pyrazinamide, always keeping ethambutol, adding streptomycin and another drug which could be isoniazid, rifampin or ofloxacin.^[@r32]^

ADVERSE EVENTS
==============

Adverse events can be divided into two major groups: (1) minor adverse events (5-20% of cases), that do not necessarily require anti-TB drug suspension, (2) major adverse events (3-8 % of cases), which typically cause treatment discontinuation. Risk factors related with the major adverse events are: age (\> 30 years), alcoholism, malnutrition, previous liver disease, and AIDS.

The charts below present in a summarized form minor and major events, the drugs from the basic scheme that are most likely associated to them and the recommended conduct ([Charts 4](#t04){ref-type="table"} and [5](#t05){ref-type="table"}).

###### 

Minor adverse events in anti-tuberculosis treatment

  **Adverse events**                      **Probable causal drug(s)**   **Conduct**
  --------------------------------------- ----------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Nausea, vomit, abdominal pain           Rifampicin                    Reschedule time of drug administration (2h after breakfast or with breakfast); consider using symptomatic medication; assess liver function
  Isoniazid                                                             
  Pyrazinamide                                                          
  Ethambutol                                                            
  Sweating/red urine                      Rifampicin                    Advise the patient
  Pruritus or light exanthema             Isoniazid                     Prescribe antihistaminic drugs
  Rifampicin                                                            
  Articular pain                          Pyrazinamide                  Prescribe analgesics and Non-steroidal anti-inflammatory drugs (NSAID)
  Isoniazid                                                             
  Peripheral neuropathy                   Isoniazid (common)            Prescribe pyridoxine (Vitamin B6) 50 mg/day
  Ethambutol (uncommon)                                                 
  Asymptomatic hyperuricemia              Pyrazinamide                  Prescribe diet low in purine
  Hyperuricemia with arthralgia           Pyrazinamide                  Prescribe diet low in purine and medicate with allopurinol and colchicine, if necessary
  Ethambutol                                                            
  Headache, Anxiety, euphoria, insomnia   Isoniazid                     Advise the patient
  Fever                                   Rifampicin                    Advise the patient
                                          Isoniazid                      

###### 

Minor adverse events in anti-tuberculosis treatment

  **Adverse events**                                                                          **Probable causal drug(s)**   **Conduct**
  ------------------------------------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Exanthema or moderate to sever hypersensibility                                             Rifampicin                    Suspend treatment; reintroduce each drug separately after resolution; in severe cases or relapses replace scheme by others without the causal drug
  Isoniazid                                                                                                                 
  Pyrazinamide                                                                                                              
  Ethambutol                                                                                                                
  Streptomycin                                                                                                              
  Psychosis, seizures, toxic encephalopathy or coma                                           Isoniazid                     Suspend Isoniazid and restart special scheme without it
  Optical neuritis                                                                            Ethambutol                    Suspend drug and restart special scheme without it. This reaction is dose-dependent, and when detected early it is reversible. It is rare to develop ocular toxicity in the first two months with the recommended doses.
  Isoniazid                                                                                                                 
  Hepatotoxicity                                                                              Pyrazinamide                  Suspend treatment; wait for symptom resolution and liver enzyme levels to decrease; reintroduce drugs separately after assessing hepatic function.
  Isoniazid                                                                                                                 
  Rifampicin                                                                                                                
  Hypoacusis Vertigo, nystagmus                                                               Streptomycin                  Suspend Streptomycin and restart special scheme without it
  Thrombocytopenia, leukopenia, eosinophilia, hemolytic anemia, agranulocytosis, vasculitis   Rifampicin                    Suspend treatment and restart special scheme without the causal medication
  Isoniazid                                                                                                                 
  Interstitial nephritis                                                                      Rifampicin                    Suspend treatment and restart special scheme without the causal medication
  Pyrazinamide                                                                                                              
  Rhabdomyolysis with myoglobinuria and kidney failure                                        Pyrazinamide                  Suspend Pyrazinamide and restart special scheme without it

Hepatitis: the drugs used to treat tuberculosis have interactions among themselves and with other drugs, which increases the risk of hepatotoxicity. In the first two months of treatment, an asymptomatic elevation of hepatic enzymes serum levels can be observed in a small percentage of patients, followed by spontaneous normalization without any clinical manifestation and without the need to interrupt or change the therapeutic regimen.

Treatment should be stopped only if hepatic enzyme levels reach three times the normal value, with onset of symptoms, or as soon as jaundice appears. The patient should then be directed to a secondary unit of reference for clinical and laboratory evaluation, besides having an adjustment in treatment, if necessary. Assuming that, after cessation of treatment, there is a reduction in serum levels of liver enzymes and resolution of symptoms, the reintroduction of the Basic Scheme is indicated, as follows: Rifampicin + Ethambutol, followed by isoniazid and lastly, pyrazinamide, with interval of three to seven days between them.

Reintroduction of each drug should be preceded by an analysis of liver function. The length of treatment will be considered from the date on which it was possible to resume the full treatment regimen. If the levels of liver enzymes do not decrease to less than three times the normal upper limit in four weeks, or if it is a severe case of tuberculosis, the alternative scheme, as described in the text on liver disease, should be started.

QUESTIONS
=========

1. Regarding the diagnosis of cutaneous tuberculosis, it can be stated that:
----------------------------------------------------------------------------

**a)** Histopathology is elucidative

**b)** Diagnostic methods have high sensitivity and specificity

**c)** Tuberculin skin test and chest X-ray examinations are mandatory

**d)** The diagnosis is based only on the positive tuberculin test

2. In which type of cutaneous tuberculosis cited below is the tuberculin test most often negative:
--------------------------------------------------------------------------------------------------

**a)** Orificial tuberculosis

**b)** Tuberculosis verrucosa

**c)** Lupus vulgaris

**d)** Scrofuloderma

3. It is true about AFB culture:
--------------------------------

**a)** It has lost its importance with the emergence of new diagnostic methods

**b)** Radioimmunometric media have a higher percentage of positive results than the traditional medium

**c)** Traditional culture is carried out in the same manner as that of other bacteria

**d)** The result is not influenced by clinical form

4. PCR has gained importance in complementing the diagnosis of CTB. Select the correct answer:
----------------------------------------------------------------------------------------------

**a)** All types of PCR have the same sensitivity

**b)** This test is the gold standard to diagnose paucibacillary forms

**c)** Spoligotyping is the gold standard for Mtb genotyping

**d)** In situ exam has superior results compared to the conventional technique

5. Regarding direct bacilloscopy, in which of the cutaneous tuberculoses described below is its positivity greater:
-------------------------------------------------------------------------------------------------------------------

**a)** Tuberculous chancre

**b)** Tuberculosis verrucosa

**c)** Tuberculids

**d)** Metastatic tuberculous abscess

6. Mark the false alternative regarding cutaneous tuberculosis laboratory diagnosis:
------------------------------------------------------------------------------------

**a)** Tuberculin test only identifies individuals who have been sensitized to TB and does not confirm active TB infection

**b)** Culture from a lesion tissue fragment is the gold standard for the diagnosis of cutaneous tuberculosis

**c)** Direct exam has a higher diagnostic yield in wet or exudative lesions that have a high bacterial load, such as primary TB inoculation, scrofuloderma, orificial tuberculosis, tuberculous or metastatic abscesses

**d)** Interferon-gamma release assays are serological tests performed to diagnose active infection by measuring the interferon-gamma secreted from peripheral blood polymorphonuclear cells after Mtb antigen exposure

7. The technique based on DNA polymorphism in M. tuberculosis direct repetition (DR) locus is:
----------------------------------------------------------------------------------------------

**a)** RFLP

**b)** Spoligotyping

**c)** MIRU-VNTR

**d)** PCR with hybridization

8. The Mtb genotyping method that uses repetition genetic loci is:
------------------------------------------------------------------

**a)** Real-time PCR

**b)** Spoligotyping

**c)** RFLP

**d)** MIRU-VNTR

9. The genotyping method in which there is DNA cleavage with restriction enzymes is:
------------------------------------------------------------------------------------

**a)** Real-time PCR

**b)** Spoligotyping

**c)** RFLP

**d)** MIRU-VNTR

10. An area of necrosis, accompanied by granulomatous infiltrate, leukocytoclastic vasculitis, perivascular edema and/or follicular necrosis with suppuration, is generally seen on:
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**a)** Scrofuloderma

**b)** Papulonecrotic tuberculid

**c)** Lupus vulgaris

**d)** Orificial tuberculosis

11. Forty-five year old male patient presents plaques consisting of asymptomatic, indurated, grouped, follicular papules, measuring 1-5 mm, with a red-brownish color, located on the torso. Anatomopathological exam showed epithelioid granulomas, surrounded by lymphocytes and located more superficially in the dermis, adjacent to the adnexa. This is probably a case of:
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**a)** Scrofuloderma

**b)** Tuberculosis verrucosa

**c)** Lichen scrofulosorum

**d)** Lupus vulgaris

12. Histopathological exam is of great importance in the diagnosis of cutaneous tuberculosis. In this context, the following statement is false:
------------------------------------------------------------------------------------------------------------------------------------------------

**a)** In all samples one can find the typical tuberculoid granuloma, caseous necrosis and lymphocytes in varying proportions.

**b)** Histopathological exam reflects the host\'s immunological response to Mtb

**c)** It is possible to not distinguish between cases of cutaneous tuberculosis and other granulomatous diseases.

**d)** Confronted with a highly suggestive exam, the clinician must continue the investigation, with other complementary exams to increase diagnostic accuracy.

13. Besides the traditional tuberculoid granuloma, the following are granulomatous patterns that may be present in CTB, except:
-------------------------------------------------------------------------------------------------------------------------------

**a)** Annular granuloma

**b)** Sarcoid granuloma

**c)** Elastolytic granuloma

**d)** Suppurative granuloma

14. Which is the therapeutic scheme recommended to treat cutaneous tuberculosis since 2009:
-------------------------------------------------------------------------------------------

**a)** Rifampicin, isoniazid, pyrazinamide in the first two months; rifampicin and isoniazid for 4 more months

**b)** Rifampicin, isoniazid, pyrazinamide and ethambutol in the first 4 months; rifampicin and isoniazid for 2 more months

**c)** Rifampicin, isoniazid, pyrazinamide and ethambutol in the first two months; Rifampicin and isoniazid for 4 more months

**d)** Rifampicin, isoniazid, pyrazinamide and ethambutol in the first two months; Rifampicin and isoniazid for 4 more months for children and adults, regardless of age and weight

15. Which minor adverse events are caused by cutaneous tuberculosis therapeutic scheme
--------------------------------------------------------------------------------------

**a)** Hypoacusis, exanthema, abdominal pain

**b)** Exanthema, peripheral neuropathy and abdominal pain

**c)** Psychosis, thrombocytopenia, hepatotoxicity

**d)** Rhabdomyolysis, fever, seizures

16. Which medications listed below should be avoided during pregnancy:
----------------------------------------------------------------------

**a)** Streptomycin and ethionamide

**b)** Ethambutol and ethionamide

**c)** Ethambutol and Streptomycin

**d)** Ofloxacin and isoniazid

17. Which of the drugs below is the least hepatotoxic:
------------------------------------------------------

**a)** Ethambutol

**b)** Rifampicin

**c)** Isoniazid

**d)** Pyrazinamide

18. Mark the correct alternative regarding the link between drug and adverse event:
-----------------------------------------------------------------------------------

**a)** Isoniazid and psychosis

**b)** Pyrazinamide and peripheral neuritis

**c)** Ethambutol and hypoacusis

**d)** Rifampicin and optical neuritis

19. Choose the correct alternative on hepatotoxicity caused by the tuberculosis treatment regimen:
--------------------------------------------------------------------------------------------------

**a)** Treatment for cutaneous tuberculosis should be stopped only when transaminases levels double their values or when clinical jaundice is present

**b)** When changes in transaminases are detected, discontinue treatment immediately and replace the scheme by less hepatotoxic drugs

**c)** When changes in transaminases are detected, discontinue treatment immediately and return to the scheme without ethambutol, as soon as liver enzyme levels return to normal

**d)** When changes in transaminases are detected, discontinue treatment immediately and reintroduce the basic scheme, as follows: Rifampicin + Ethambutol, followed by isoniazid and lastly, pyrazinamide, with an interval of three to seven days in between, as soon as the transaminases return to normal

20. Hypoacusis, nystagmus and vertigo are symptoms observed in the treatment of tuberculosis with:
--------------------------------------------------------------------------------------------------

**a)** Rifampicin

**b)** Isoniazid

**c)** Streptomycin

**d)** Ethambutol

###### 
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  ------- -------- -------- --------
  1\) B   6\) B    11\) B   16\) C
  2\) D   7\) C    12\) A   17\) D
  3\) A   8\) D    13\) D   18\) D
  4\) C   9\) B    14\) A   19\) D
  5\) D   10\) D   15\) C   20\) B
  ------- -------- -------- --------

Papers
------

Information for all members: The EMC-D questionnaire is now available at the homepage of the Brazilian Annals of Dermatology: [www.anaisdedermatologia.org.br](www.anaisdedermatologia.org.br). The deadline for completing the questionnaire is 30 days from the date of online publication.
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